You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Express Scripts
Baxter
Mallinckrodt

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SELPERCATINIB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Selpercatinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Not yet recruiting Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company Phase 3 2019-12-10 The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Not yet recruiting Eli Lilly and Company Phase 3 2019-12-10 The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
NCT04211337 A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Not yet recruiting Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company Phase 3 2019-12-24 The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body.
NCT04211337 A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Not yet recruiting Eli Lilly and Company Phase 3 2019-12-24 The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body.
NCT04268550 Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Not yet recruiting National Cancer Institute (NCI) Phase 2 2020-03-07 This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Selpercatinib

Condition Name

Condition Name for Selpercatinib
Intervention Trials
Medullary Thyroid Cancer 2
Refractory Lymphoma 1
Healthy 1
Thyroid Gland Papillary Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Selpercatinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 3
Thyroid Neoplasms 3
Thyroid Diseases 3
Carcinoma, Neuroendocrine 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Selpercatinib

Trials by Country

Trials by Country for Selpercatinib
Location Trials
United States 37
China 34
Germany 17
Italy 13
Brazil 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Selpercatinib
Location Trials
Texas 4
Massachusetts 3
Florida 3
California 3
Oregon 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Selpercatinib

Clinical Trial Phase

Clinical Trial Phase for Selpercatinib
Clinical Trial Phase Trials
Phase 3 3
Phase 2 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Selpercatinib
Clinical Trial Phase Trials
Not yet recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Selpercatinib

Sponsor Name

Sponsor Name for Selpercatinib
Sponsor Trials
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company 5
Eli Lilly and Company 5
National Cancer Institute (NCI) 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Selpercatinib
Sponsor Trials
Other 7
Industry 5
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Medtronic
McKesson
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.